摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloromethyl-α-methyldiphenylmethane | 120261-82-7

中文名称
——
中文别名
——
英文名称
4-chloromethyl-α-methyldiphenylmethane
英文别名
1-(Chloromethyl)-4-(1-phenylethyl)benzene
4-chloromethyl-α-methyldiphenylmethane化学式
CAS
120261-82-7
化学式
C15H15Cl
mdl
——
分子量
230.737
InChiKey
CTORVOGTKOCPMN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

文献信息

  • Novel aminodicarboxylic acid derivatives having pharmaceutical properties
    申请人:Alonso-Alija Cristina
    公开号:US20060094769A1
    公开(公告)日:2006-05-04
    The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.
    本发明涉及以下式子(II),(IV)和(VI)的化合物,其中各个变量基团如规范和要求中所定义。还公开了制备这些材料的过程以及将它们用于合成治疗心血管疾病和纤维化疾病的化合物的方法。
  • Novel dicarboxylic acid derivatives with pharmaceutical properties
    申请人:Alonso-Alija Cristina
    公开号:US20080058314A1
    公开(公告)日:2008-03-06
    The present invention relates to the use of compounds of the formula (I) and to their salts and stereoisomers, for the preparation of medicaments for the treatment of cardiovascular disorders.
    本发明涉及使用式(I)的化合物及其盐和立体异构体,用于制备治疗心血管疾病的药物。
  • NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES
    申请人:Alonso-Alija Cristina
    公开号:US20100317854A1
    公开(公告)日:2010-12-16
    The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.
    本发明涉及以下式子的化合物(II),(IV)和(VI),其中各个变量组在规范和要求中定义。还公开了制备这些材料的过程,以及在合成用于治疗心血管疾病和纤维化疾病的化合物的方法。
  • Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents
    申请人:MITSUI TOATSU CHEMICALS, Inc.
    公开号:EP0268878A2
    公开(公告)日:1988-06-01
    Disclosed herein are salicylic acid copolymers having a weight average molecular weight of 500 10,000 and obtained (a) by condensing salicylic acid (i) with a benzyl alcohol (ii) and/or benzyl ether (iii) or a benzyl halide (iv) in the presence of an acid catalyst or (b) by reacting a co-condensation resin of (i) and (ii) and/or (iii) with (iv) or (c) by reacting a co-condensation resin of (i) and (ii) and/or (iii) or (iv) with a styrene derivative in the presence of an acid catalyst; multivalent metal salts of the salicylic acid copolymers; color-developing agents comprising the multivalent metal salts; and color-developing sheets suited for pressure-sensitive copying paper and comprising the color-developing agents. Their production processes are also disclosed.
    本文公开了水杨酸共聚物,其重量平均分子量为 500 10、000 的水杨酸共聚物;(a)在酸催化剂存在下,将水杨酸(i)与苄醇(ii)和/或苄醚(iii)或苄基卤化物(iv)缩合而得,或(b)将(i)和(ii)和/或(iii)的共缩合树脂与(iv)反应而得,或(c)在酸催化剂存在下,将(i)和(ii)和/或(iii)或(iv)的共缩合树脂苯乙烯生物反应而得;水杨酸共聚物的多价属盐;由多价属盐组成的显色剂;以及由显色剂组成的适用于压敏复印纸的显色薄片。此外,还公开了它们的生产工艺。
  • Color-developing compositions and their use
    申请人:MITSUI TOATSU CHEMICALS, Inc.
    公开号:EP0523697A1
    公开(公告)日:1993-01-20
    A color-developing composition comprises a multivalent-metal-modified salicylic acid resin (Resin A) and a polycondensation resin (resin B) at a weight ratio of 90-30 to 10-70. Resin A is composed of 5-35 mole% of a structural unit (I) and 65-95 mole% of at least one structural unit (II) or 65-95 mole% of a coupled structural unit of at least one unit (II) and at least one unit (III) and has a weight-average molecular weight of 350-5,000. Resin B is composed of the unit (II) and/or the unit (III) and has a weight-average molecular weight of 350-5,000. wherein Z represents M/m, M being a metal ion of m valence and m being an integer; R₁ and R₂ represent H or a C₁₋₁₂ alkyl, aralkyl, aryl or cycloalkyl group; R₃ and R₆ represent H or a C₁₋₄ alkyl group; and R₄ and R₅ represent H or CH₃.
    一种显色组合物包括一种多价属改性水杨酸树脂树脂 A)和一种缩聚树脂树脂 B),两者的重量比为 90-30 比 10-70。树脂 A 由 5-35 摩尔%的结构单元(I)和 65-95 摩尔%的至少一个结构单元(II)或 65-95 摩尔%的至少一个单元(II)和至少一个单元(III)的耦合结构单元组成,其重量平均分子量为 350-5000。树脂 B 由单元(II)和/或单元(III)组成,重量平均分子量为 350-5000。 其中 Z 代表 M/m,M 为 m 价属离子,m 为整数;R₁ 和 R₂ 代表 H 或 C₁₋₁₂ 烷基、芳基、芳烷基或环烷基;R₃ 和 R₆ 代表 H 或 C₁₋₄ 烷基;以及 R₄ 和 R₅ 代表 H 或 CH₃。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫